




The relative strengths and weaknesses of Juniper Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Juniper Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Juniper Pharmaceuticals INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 371%, being 129% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	32,227
Cost of Goods Sold	13,251
Intangible Assets	13,980
Liabilities, Current	6,297
Liabilities, Non-Current	0
Other Assets	659
Other Compr. Net Income	1,087
Other Expenses	1,291
Other Liabilities	6,367
Other Net Income	57
Other Revenues	29,226
Property and Equipment	13,226
Research and Development	0
Selling, General and Administrative Expense	8,038

Output Variable	Value in 1000 USD
Assets	60,092
Liabilities	12,665
Expenses	22,580
Revenues	29,226
Stockholders Equity	47,428
Net Income	6,704
Comprehensive Net Income	7,247
BaseVar	62,854
ECR before Limited Liability	304%
Economic Capital Ratio	371%